Sail Biomedicines

📍 Cambridge, United States👥 107 employees💰 Last funded Sep 2019
Biotechnology Research🌐 sail.bio
Website LinkedIn
Sail Biomedicines is creating a new class of RNA medicines designed to instruct therapeutic activity directly inside a patient’s body and within selected cells. Sail’s platform integrates Endless RNA™ (eRNA™), targeted nanoparticle delivery, and AI-enabled design to develop medicines with optimized therapeutic performance. The company is focused on applying its platform to In Vivo CAR-T medicines for immune-mediated diseases, with the goal of bringing the curative potential of CAR-T cell therapy to substantially more patients. Sail was founded by Flagship Pioneering and is headquartered in Cambridge, Massachusetts.
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Sail Biomedicines?
Sail Biomedicines has 2 investors on record on gritt.io.
When did Sail Biomedicines last raise funding?
The most recent investment in Sail Biomedicines recorded on gritt.io was in September 2019.
What industry is Sail Biomedicines in?
Sail Biomedicines operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Sail Biomedicines based?
Sail Biomedicines is headquartered in Cambridge, United States.